

Dimitrios T Trafalis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9128372/publications.pdf>

Version: 2024-02-01

70
papers

1,721
citations

567144

15
h-index

552653

26
g-index

70
all docs

70
docs citations

70
times ranked

3126
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Bioactive Properties of Lipophilic Fractions of Edible and Non-Edible Parts of <i>Nasturtium officinale</i> (Watercress) in a Model of Human Malignant Melanoma Cells. <i>Pharmaceuticals</i> , 2022, 15, 141.	1.7	9
2	Assessment of Methodological Pipelines for the Determination of Isothiocyanates Derived from Natural Sources. <i>Antioxidants</i> , 2022, 11, 642.	2.2	5
3	In silico study of potential antiviral activity of copper(II) complexes with non-steroidal anti-inflammatory drugs on various SARS-CoV-2 target proteins. <i>Journal of Inorganic Biochemistry</i> , 2022, 231, 111805.	1.5	7
4	The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research. <i>International Journal of Molecular Sciences</i> , 2022, 23, 436.	1.8	8
5	Silver complexes bearing heterocyclic thioamide ligands with NH ₂ and CF ₃ substituents: effect of ligand group substitution on antibacterial and anticancer properties. <i>Dalton Transactions</i> , 2022, 51, 9412-9431.	1.6	6
6	The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum. <i>Journal of Clinical Medicine</i> , 2022, 11, 3417.	1.0	5
7	The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 531-549.	1.3	0
8	Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma. <i>European Journal of Nutrition</i> , 2021, 60, 147-158.	1.8	26
9	The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 191-213.	1.0	3
10	An Evaluation of the Anti-Carcinogenic Response of Major Isothiocyanates in Non-Metastatic and Metastatic Melanoma Cells. <i>Antioxidants</i> , 2021, 10, 284.	2.2	6
11	Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1097-1120.	1.4	5
12	Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. <i>Pharmaceuticals</i> , 2021, 13, 493.	2.0	3
13	Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins. <i>Current Medicinal Chemistry</i> , 2021, 28, 1443-1467.	1.2	4
14	Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma. <i>Investigational New Drugs</i> , 2021, 39, 1460-1468.	1.2	9
15	Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins. <i>Future Medicinal Chemistry</i> , 2021, 13, 877-895.	1.1	6
16	Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay. <i>Biomedicines</i> , 2021, 9, 1028.	1.4	2
17	Synthesis and Biological Evaluation of a c(RGDyK) Peptide Conjugate of SRPIN803. <i>ACS Omega</i> , 2021, 6, 28379-28393.	1.6	1
18	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. <i>Cancers</i> , 2021, 13, 5277.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden. <i>Pharmaceutics</i> , 2021, 13, 885.	2.0	1
20	Charting the Unknown Association of COVID-19 with Thyroid Cancer, Focusing on Differentiated Thyroid Cancer: A Call for Caution. <i>Cancers</i> , 2021, 13, 5785.	1.7	7
21	Chemical and Biological Characterization of the Anticancer Potency of <i>Salvia fruticosa</i> in a Model of Human Malignant Melanoma. <i>Plants</i> , 2021, 10, 2472.	1.6	3
22	Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma. <i>European Journal of Nutrition</i> , 2020, 59, 557-569.	1.8	24
23	Harnessing the versatile role of OPC in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 13-30.	1.7	16
24	Discovery of steroidal lactam conjugates of POPAM-NH ₂ with potent anticancer activity. <i>Future Medicinal Chemistry</i> , 2020, 12, 19-35.	1.1	5
25	Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event. <i>International Immunopharmacology</i> , 2020, 89, 107050.	1.7	7
26	Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1235-1252.	1.3	1
27	3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7369-7386.	1.0	5
28	Prophylactic lymph node dissection in clinically NO differentiated thyroid carcinoma: example of personalized treatment. <i>Personalized Medicine</i> , 2020, 17, 317-338.	0.8	1
29	Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1331-1346.	1.4	5
30	How Far Are We from Prescribing Fasting as Anticancer Medicine?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9175.	1.8	16
31	Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma. <i>Cancers</i> , 2020, 12, 1263.	1.7	4
32	Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 305-310.	0.6	9
33	Silver complexes with heterocyclic thioamide and tertiary arylphosphane ligands: Synthesis, crystal structures, in vitro and in silico antibacterial and cytotoxic activity, and interaction with DNA. <i>Journal of Inorganic Biochemistry</i> , 2020, 210, 111167.	1.5	12
34	Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106427.	1.7	23
35	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. <i>Immunotherapy</i> , 2020, 12, 481-510.	1.0	7
36	8-Hydroxy-2'-Deoxyguanosine and 8-Nitroguanine Production and Detection in Blood Serum of Breast Cancer Patients in Response to Postoperative Complementary External Ionizing Irradiation of Normal Tissues. <i>Dose-Response</i> , 2020, 18, 155932582098217.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?. <i>Jbuon</i> , 2020, 25, 1-14.	0.3	6
38	Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. <i>International Immunopharmacology</i> , 2019, 77, 105942.	1.7	11
39	The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents. <i>Antioxidants</i> , 2019, 8, 106.	2.2	80
40	A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer. <i>Medicine (United States)</i> , 2019, 98, e14989.	0.4	7
41	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
42	Synthesis and anticancer activity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives. <i>Arabian Journal of Chemistry</i> , 2019, 12, 4784-4794.	2.3	27
43	Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2018, 41, 300-305.	1.2	31
44	Novel Docosahexaenoic Acid Ester of Phloridzin Inhibits Proliferation and Triggers Apoptosis in an In Vitro Model of Skin Cancer. <i>Antioxidants</i> , 2018, 7, 188.	2.2	8
45	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. <i>Clinical Drug Investigation</i> , 2018, 38, 639-648.	1.1	20
46	Bevacizumab, temsirolimus plus or without cetuximab: combinational treatment against patients with advanced HNSCC. <i>Journal of B U on</i> , 2018, 23, 1928-1929.	0.4	0
47	A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 717-725.	1.2	3
48	Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells. <i>Chemical Biology and Drug Design</i> , 2017, 90, 854-866.	1.5	7
49	Evidence of the role of the vagal nerves as a monitor in the gastrointestinal-renal axis of natriuresis in human: Effects of vagotomy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 205, 99-109.	1.4	0
50	Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model. <i>Anti-Cancer Drugs</i> , 2017, 28, 489-502.	0.7	1
51	Synthesis and biological evaluation of a Platinum(II)-c(RGDyK) conjugate for integrin-targeted photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 221-231.	2.6	38
52	Synthesis and analysis of the anticancer activity of Ru(II) complexes incorporating 2-hydroxymethylidene-indene-1,3-dione ligands. <i>New Journal of Chemistry</i> , 2017, 41, 10438-10446.	1.4	4
53	Novel c(RGDyK)-based conjugates of POPAM and 5-fluorouracil for integrin-targeted cancer therapy. <i>Future Medicinal Chemistry</i> , 2017, 9, 2181-2196.	1.1	10
54	Nestin and CD146 expression in metaplastic breast cancer: stem-cell therapy in need? Lessons reported from a male patient. <i>European Review for Medical and Pharmacological Sciences</i> , 2017, 21, 4137-4140.	0.5	3

#	ARTICLE	IF	CITATIONS
55	Synthesis and evaluation of new steroidal lactam conjugates with aniline mustards as potential antileukemic therapeutics. <i>Steroids</i> , 2016, 115, 1-8.	0.8	18
56	Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 713-722.	1.1	20
57	Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I. <i>Journal of B U on</i> , 2016, 21, 764-779.	0.4	9
58	Glioblastoma multiforme: Pathogenesis and treatment. , 2015, 152, 63-82.		588
59	Combination of three cytotoxic agents in small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 413-418.	1.1	4
60	Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab. <i>Anti-Cancer Drugs</i> , 2012, 23, 874-882.	0.7	2
61	Saffron as a Source of Novel Acetylcholinesterase Inhibitors: Molecular Docking and in Vitro Enzymatic Studies. <i>Journal of Agricultural and Food Chemistry</i> , 2012, 60, 6131-6138.	2.4	143
62	In silico/in vitro study of hybrid D-modified steroidal alkylator anticancer activity using uridine phosphorylase as target protein. <i>Anticancer Research</i> , 2011, 31, 831-42.	0.5	6
63	Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. <i>Anti-Cancer Drugs</i> , 2010, 21, 202-205.	0.7	10
64	Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study. <i>Oncology Letters</i> , 2010, 1, 335-338.	0.8	3
65	CYP2E1 and risk of chemically mediated cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 307-319.	1.5	57
66	Carbamazepine Can Be Effective in Alleviating Tormenting Pruritus in Patients with Hematologic Malignancy. <i>Journal of Pain and Symptom Management</i> , 2008, 35, 571-572.	0.6	16
67	Hybrid aza-steroid alkylators in the treatment of colon cancer. <i>Cancer Letters</i> , 2006, 243, 202-210.	3.2	22
68	Stauffer's syndrome variant associated with renal cell carcinoma. <i>International Journal of Urology</i> , 2005, 12, 757-759.	0.5	32
69	On the formation of 4-[N,N-bis(2-chloroethyl)amino]phenyl acetic acid esters of hecogenin and aza-homo-hecogenin and their antileukemic activity. <i>Il Farmaco</i> , 2005, 60, 826-829.	0.9	10
70	Aneuploidy of chromosome 20 in invasive breast cancer correlates with poor outcome. <i>Cancer Genetics and Cytogenetics</i> , 2002, 134, 127-132.	1.0	10